Alaunos Therapeutics, Inc. (TCRT) Operating cash flow 2016–2025
Alaunos Therapeutics, Inc. (TCRT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$2.9MFY2025 · since FY2016: -$58.3M → -$2.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$2.9M | +42.3% |
| FY2024 | -$5.0M | +83.5% |
| FY2023 | -$30.1M | -3.1% |
| FY2022 | -$29.2M | +52.4% |
| FY2021 | -$61.5M | -7.8% |
| FY2020 | -$57.0M | -39.6% |
| FY2019 | -$40.9M | +17.4% |
| FY2018 | -$49.5M | +9.5% |
| FY2017 | -$54.7M | +6.3% |
| FY2016 | -$58.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRT financial trends
TCRT RevenueTCRT Net incomeTCRT Net marginTCRT Gross profitTCRT Gross marginTCRT Operating incomeTCRT Operating marginTCRT Free cash flowTCRT Capital expendituresTCRT Return on equityTCRT Stock buybacksTCRT Dividends paidTCRT Total assetsTCRT Total liabilitiesTCRT Shareholders’ equityTCRT overview →